Premium
Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia—cryoprecipitate or fibrinogen concentrate?
Author(s) -
Cushing Melissa M.,
Haas Thorsten,
Karkouti Keyvan,
Callum Jeannie
Publication year - 2020
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.15614
Subject(s) - cryoprecipitate , hypofibrinogenemia , fibrinogen , medicine , hemostasis , coagulation , blood product , surgery
The importance of the targeted treatment of acquired hypofibrinogenemia during hemorrhage with a concentrated fibrinogen product (either cryoprecipitate or fibrinogen concentrate) cannot be underestimated. Fibrinogen concentrate is a pathogen inactivated, pooled product that offers a highly purified single factor concentrate. Cryoprecipitate is a pooled product that comes with a spectrum of other coagulation factors which may further enhance (additional procoagulant effect) or even disturb (prothrombotic risk) hemostasis. The pros and cons of each product are discussed.